Palisade Bio Inc
Research Palisade Bio Inc (PALI) on Bullrun: market cap USD 387.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPALI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 387.53M
- Financial periodFY2025
- Net income-USD 16.78M
Valuation Snapshot
latest market cap is USD 387.53M.
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc.
Frequently asked questions
What is Palisade Bio Inc's market cap?
Palisade Bio Inc's market capitalization is USD 387.53M.
What does Palisade Bio Inc do?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.